Sign In
Buy OPRX
$4.95
-0.330 (-6.25%)
At Close: Jun 03, 2026
Nasdaq Drops 200 Points; Meta Platforms Shares Jump
07:24pm, Wednesday, 09'th Nov 2022 Benzinga
U.S. stocks traded lower toward the end of trading , with the Nasdaq Composite dropping 200 points on Wednesday.
The Dow traded down 1.44% to 32,684.65 while the NASDAQ fell 1.89% to 10,416.00. The S&
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
05:33pm, Wednesday, 09'th Nov 2022 Benzinga
Gainers
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares jumped 219% to $12.80 after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimack is eligible for up to $
Crude Oil Down Over 2%; Outset Medical Shares Spike Higher
05:19pm, Wednesday, 09'th Nov 2022 Benzinga
U.S. stocks traded lower midway through trading as investors focused on the outcome of the midterm elections.
The Dow traded down 0.64% to 32,950.16 while the NASDAQ fell 0.76% to 10,535.77. The S&P 5
Meta Platforms, Hilton Grand Vacations, D.R. Horton, And Some Other Big Stocks Moving Higher On Wednesday
03:54pm, Wednesday, 09'th Nov 2022 Benzinga
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Wednesday. Here are some big stocks recording gains in today’s session.
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) sh
OptimizeRx Corporation (OPRX) Q3 2022 Earnings Call Transcript
12:56am, Wednesday, 09'th Nov 2022
OptimizeRx Corporation (NASDAQ:OPRX ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Will Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial and Operating
OptimizeRx Corp. (OPRX) Tops Q3 Earnings Estimates
10:35pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 75% and 0.47%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Tops Q3 Earnings Estimates
06:48pm, Tuesday, 08'th Nov 2022
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 75% and 0.47%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analyst Ratings for OptimizeRx
06:07pm, Tuesday, 01'st Nov 2022 Benzinga
Within the last quarter, OptimizeRx (NASDAQ:OPRX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
1
0
0
Last 30D
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
02:27pm, Tuesday, 01'st Nov 2022 Benzinga
Upgrades
For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto
OptimizeRx Sets Third Quarter Fiscal 2022 Conference Call for Tuesday, November 8 at 4:30 p.m. ET
08:05pm, Wednesday, 19'th Oct 2022 GlobeNewswire Inc.
ROCHESTER, Mich., Oct. 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on
OptimizeRx Sets Third Quarter Fiscal 2022 Conference Call for Tuesday, November 8 at 4:30 p.m. ET
04:05pm, Wednesday, 19'th Oct 2022
ROCHESTER, Mich., Oct. 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on t
OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio
06:46am, Wednesday, 12'th Oct 2022
OptimizeRx has lost roughly 83% over the past twelve months despite showing impressive growth and profitability metrics. The market-wide sell-off is providing an opportunity to establish a position in
OptimizeRx Reports Results of Flagship Evidence-Based Physician Engagement Program
01:18pm, Tuesday, 23'rd Aug 2022 GlobeNewswire Inc.
Analysis finds patent-pending real-world evidence solution successful in identifying HCPs with patients at risk of non-adherence due to unexpected cost.
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
09:28am, Thursday, 11'th Aug 2022 Benzinga
Gainers
Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.
BioAtla, Inc. (NASDAQ: BCAB) jumped 83.1% to close at $6.61 on Wednesd
Nasdaq Surges Over 300 Points; Trade Desk Shares Spike Higher
06:36pm, Wednesday, 10'th Aug 2022 Benzinga
U.S. stocks traded higher toward the end of trading, following the release of inflation data.
The Dow traded up 1.42% to 33,240.49 while the NASDAQ rose 2.63% to 12,822.69. The S&P also rose, gaining,
